Drug intelligence / Profile preview

autologous bronchial basal cells

Development stage
Phase 2
Lead developer
Regend Therapeutics
Modality
Stem Cell Therapies → Cell Therapies
Administration
Inhalation
01

Overview

Autologous bronchial basal cells (REGEND001) is an autologous stem cell therapy developed by Regend Therapeutics for the treatment of chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and bronchiectasis. The therapeutic process involves isolating basal cells from the patient's own bronchi via fiberoptic bronchoscopy or brushing, expanding these cells ex vivo, and then transplanting them back into the patient's pulmonary lesions. These cells serve as progenitor cells capable of regenerating bronchial and alveolar structures, thereby repairing damaged lung tissue and potentially restoring pulmonary function in patients with progressive respiratory failure.

Other names
autologous bronchial basal cell transplantationautologous lung stem cell transplantationautologous self-repairing airway epithelial cellsBBCs

Beyond the preview

Go deeper on autologous bronchial basal cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous bronchial basal cells.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call